samedan logo
 
 
 
spacer
home > ebr > autumn 2021 > advancing affordable orphan drug development
PUBLICATIONS
European Biopharmaceutical Review

Advancing Affordable Orphan Drug Development

EBR: What are the key challenges in access to, and affordability of, medicines for orphan diseases, and how can they be tackled?

Haishan Jang: One of the most difficult challenges of orphan drug development is the small number of patients available. Regulatory agencies allow for fewer patient participants in trials, but there are relatively high costs in patient recruitment, trial design, and manufacturing small batches of a drug. However, as more orphan drugs reach the clinic, data are starting to show that with the right team and regulatory strategy, orphan drug development is, on average, less expensive than traditional drugs.

Since around 90% of rare diseases have no available medicines, patients lack treatment options, and physicians don’t have experience in diagnosing and treating the diseases. With limited market size, it is understandable that many companies do not prioritise or allocate resources to developing new drugs for orphan disease indications. To offset development costs, treatment costs per patient can be exponential, and beyond the affordability of health agencies and insurers.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
With more than 30 years in the pharmaceutical industry, CEO of BRIM Biotechnology, Haishan Jang, was previously a member of senior management at Centocor, DuPont, and Sanofi, and was the former President at TWI Biotechnology, Taiwan. Haishan has contributed to the development of many leading drugs, including Uroxatral®, Tirazon®, Remicade®, Simponi®, and Stelara®. Her breadth of experience and translational science expertise has led BRIM to advance discoveries into the clinic, and successfully spin-out Ascendo Biotechnology, Inc. Haishan co-founded BRIM Biotechnology with Dr Frank Lee in 2013.
spacer
Haishan Jang
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Aggreko’s Matt Watson Awarded Full Membership to the Institute of Refrigeration

A temporary solutions specialist has further consolidated its position within the refrigeration sector with a key team member joining an industry-leading organisation. Matt Watson, Aggreko’s Manufacturing & HVAC Sector Sales Manager for the UK and Ireland, has joined the Institute of Refrigeration (IoR) as a full member. His membership to the institute marks a recognition of his position as a responsible industry professional and the depth of his knowledge on cooling equipment solutions.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement